Daunorubicin-TiO2 nanocomposites as a “smart” pH-responsive drug delivery system
Authors:
Open Access
- 1 January 2012
- journal article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 7, 235-242
Abstract
Daunorubicin (DNR) has a broad spectrum of anticancer activity, but is limited in clinical application due to its serious side effects. The aim of this study was to explore a novel “smart” pH-responsive drug delivery system (DDS) based on titanium dioxide (TiO2) nanoparticles for its potential in enabling more intelligent controlled release and enhancing chemotherapeutic efficiency of DNR. DNR was loaded onto TiO2 nanoparticles by forming complexes with transition metal titanium to construct DNR-TiO2 nanocomposites as a DDS. DNR was released from the DDS much more rapidly at pH 5.0 and 6.0 than at pH 7.4, which is a desirable characteristic for tumor-targeted drug delivery. DNR-TiO2 nanocomposites induced remarkable improvement in anticancer activity, as demonstrated by flow cytometry, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and nuclear 4′,6-diamidino-2-phenylindole staining. Furthermore, the possible signaling pathway was explored by western blot. For instance, in human leukemia K562 cells, it was demonstrated that DNR-TiO2 nanocomposites increase intracellular concentration of DNR and enhance its anticancer efficiency by inducing apoptosis in a caspase-dependent manner, indicating that DNR-TiO2 nanocomposites could act as an efficient DDS importing DNR into target cancer cells. These findings suggest that “smart” DNR delivery strategy is a promising approach to cancer therapy.Keywords
This publication has 14 references indexed in Scilit:
- Ultrasound mediated drug-loaded nanoparticles crossing cell membranes as a new strategy to reverse cancer multidrug resistance.Journal of Nanoscience and Nanotechnology, 2011
- Self-oscillating gel composed of thermosensitive polymer exhibiting higher LCSTJournal of Controlled Release, 2011
- A strategy for ZnO nanorod mediated multi-mode cancer treatmentBiomaterials, 2011
- Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignanciesInternational Journal of Nanomedicine, 2010
- The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicinBiomaterials, 2010
- pH-Sensitive, N-ethoxybenzylimidazole (NEBI) bifunctional crosslinkers enable triggered release of therapeutics from drug delivery carriersOrganic & Biomolecular Chemistry, 2010
- Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug deliveryBiomaterials, 2009
- The incorporation of daunorubicin in cancer cells through the use of titanium dioxide whiskersBiomaterials, 2009
- Apoptosis and cancer: mutations within caspase genesJournal of Medical Genetics, 2009
- Liposomal daunorubicin as treatment for Kaposi’s sarcoma2007